Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa

Jiménez‐Gallo, David; Varga-Martínez, Raquel de la; Ossorio-García, Lidia; Collantes‐Rodríguez, Cristina; Rodrı́guez, Carmen; Linares‐Barrios, Mario

doi:10.1016/j.cyto.2017.12.020

Cited by 28 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TNF-α levels were significantly elevated compared to control tissue in two studies 7, 31 but not significantly in 2 additional studies 4, 24 . sTNFR1 was significantly elevated in one study 26 whilst showing a non-significant difference in a second study 25 . CCL5 was significant in 2 studies in lesional tissue compared with controls 4, 26 .…”

Section: Resultsmentioning

confidence: 81%

“…In HS tissue, S100A9, hBD1 and hBD2 were reduced but this data did not meet statistical significance. Two studies measuring IL-1β levels showed no statistically significant difference between lesional and control skin 7, 25 . No significant elevation of IL-6 was seen in lesional tissue compared to control with the exception of 1 study 25 .…”

Section: Resultsmentioning

confidence: 94%

“…Two studies measuring IL-1β levels showed no statistically significant difference between lesional and control skin 7, 25 . No significant elevation of IL-6 was seen in lesional tissue compared to control with the exception of 1 study 25 . IL-8 levels only just made significance in two studies 5, 7 , with one study showing significant elevation of IL-8 in lesional compared to control tissue 24 .…”

Section: Resultsmentioning

confidence: 94%

See 2 more Smart Citations

A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa

2018

View full text Add to dashboard Cite

Background: The pathogenesis of hidradenitis suppurativa (HS) remains unclear. In order to develop effective treatment strategies, a deeper understanding of pathophysiology is needed. This is impaired by multiple small studies with inconsistent methodologies and the impact of co-occurring pro-inflammatory conditions such as smoking and obesity. Methods: This systematic review aimed to collate all published reports of cytokine studies in tissue, blood, serum and exudate. It was registered with PROSPERO (Registration number CRD42018104664) performed in line with the PRISMA checklist. Results: 19 studies were identified comprising 564 individual HS patients and 198 control patients examining 81 discrete cytokines. Methodology was highly varied and the quality of studies was generally low. There was a large degree of variance between the measured levels of cytokines. 78.2% of cytokines demonstrated heterogeneity by the chi-squared test for homogeneity and hence meta-analysis was not deemed appropriate. However, a strong and significant IL-17 signalling component was identified. Conclusions: Cytokines consistently elevated in lesional, peri-lesional and unaffected tissue are identified and discussed. Areas for further investigation include the role of dendritic cells in HS; the contribution of obesity, smoking, diabetes and the microbiome to cytokine profiles in HS; and examining the natural history of this disease through longitudinal measurements of cytokines over time.

show abstract

Section: Resultsmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 94%

See 1 more Smart Citation

A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa

2018

View full text Add to dashboard Cite

show abstract

“…15 Safety analysis of every week and EOW dosing showed similar adverse event rates. 16 Jiménez-Gallo et al 2018 156 Prospective open label study 19 (11 males, eight females) ADA 40 mg weekly 36 weeks HiSCR in 68.42%. NR Kimball et al 2012 11 Phase II parallel randomized, placebo-controlled trial with a blinded 16-week period and an open-label 36-week period 154 ADA 40 mg weekly vs 40 mg EOW vs placebo 52 weeks 17.6% in weekly ADA vs 9.6% in EOW group vs 3.9% in placebo group achieved HS-PGA score of clear, minimal, or mild with at least a two-grade improvement relative to baseline score at week 16 (EOW vs placebo difference, 5.6% [95% CI, 4.0% to 15.3%]; p 0.25; weekly vs placebo difference, 13.7% [CI, 1.7% to 25.7%]; p 0.025).…”

Section: Biologic and Other Immunomodulatory Therapiesmentioning

confidence: 99%

<p>Systematic review of immunomodulatory therapies for hidradenitis suppurativa</p>

Lim¹,

Oon²

2019

BTT

View full text Add to dashboard Cite

Background: Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in moderate/severe hidradenitis suppurativa (HS) has helped in developing new regimens. We aim to review the use of different immunomodulatory therapies used to manage HS. Methods: A comprehensive literature search was conducted on the PubMed and Clinicaltrials.gov databases from 1 January 1947 to 31 December 2018. Only clinical trials, case reports, case series and retrospective analyses published in the English language were included. Results: Our search yielded 107 articles and 35 clinical trials, of which 15 are still ongoing. The tumor necrosis factor-α inhibitors adalimumab and infliximab were the most comprehensively studied agents. Published data from clinical trials support the efficacy of adalimumab, infliximab, anakinra, ustekinumab, bermekimab and apremilast but not etanercept and MEDI8968. Clinical trials for CJM112 have been completed, with results awaiting publication. Trials are underway for secukinumab, IFX-1, INCB054707 and bimekizumab. Biologics used in smaller cohorts include canakinumab, golimumab and rituximab. Most agents are well tolerated and demonstrate a good safety profile, with the most commonly reported adverse event being infections. Discussion and conclusions: To date, adalimumab is the only biologic which has been approved by the United States Food and Drug Administration for HS. However, other agents also show promise, with further trials underway to evaluate their efficacy, tolerability and safety profiles. Different clinical measurement scores and endpoints used to make direct comparison difficult. Longitudinal surveillance and pooled registry data are paramount to evaluate the long-term safety profile and efficacy of therapy.

show abstract

“…Yapılan çalışmalarda 2. haftadan itibaren ağrı skalasında ciddi düşüş olduğu ve tedavi süresince bu iyilik halinin korunduğu belirtilmektedir26 . Bu çalışmada da literatürle uyumlu PIONEER II ve II'ye katılan ve adalimumab tedavisine devam eden hastalar 168 hafta boyunca izlenmiştir27 . Hastalarda klinik iyileşmenin ve yaşam kalitesindeki artışın uzun dönem korunduğu belirtilmekte ve uzun dönemde ilacın güvenilir olduğu vurgulanmaktadır…”

unclassified

The efficacy of adalimumab therapy in refractory hidradenitis suppurativa: Retrospective analysis

Türkmen¹

2019

TURKDERM

View full text Add to dashboard Cite

Background and Design: Hidradenitis suppurativa (HS) is a painful, chronic, inflammatory skin disease and there is no effective standard method for its treatment. The studies on the successful results of adalimumab in the treatment of HS are increasing and its use is approved by the Ministry of Health in our country. Materials and Methods: The efficacy and side effects of adalimumab were evaluated retrospectively in 9 patients who were diagnosed with resistant HS. Adalimumab was administered 40 mg subcutaneously per week. Patients were followed closely for infections and other side effects. In patients, nodules, abscesses and fistulas were determined at the beginning of the treatment, at the 4 th and 12 th week of the treatment. The values of global pain scores, life quality index scores and C-reactive protein levels recorded at the beginning and at the 12 th week of the treatment were evaluated. Results: The ages of 9 patients receiving adalimumab for severe HS were between 33-67 (mean: 50.6), and 7 of the patients were male. The disease duration ranged from 2 to 25 years (mean: 13 years) 5 of the patients according to the Hurley classification was determined as stage 2 and 4 as stage 3. In the 12 th week, the number of nodules, abscess and draining fistulas were decreased respectively 60.2%, 69.3% and 52.1%. C-reactive protein levels of 16.3 mg/L at the beginning of treatment were 5.5 mg/L at 12 weeks. Before the treatment, life quality Amaç: Hidradenitis süpürativa (HS) ağrılı, kronik, enflamatuvar bir deri hastalığı olup, tedavisinde henüz efektif bir standart yöntem bulunmamaktadır. HS tedavisinde adalimumab ile başarılı sonuçların alındığı çalışma sayısı gittikçe artmaktadır. Gereç ve Yöntem: Dirençli HS tanısıyla adalimumab başlanılan 9 hastada adalimumabın etkinliği, yan etkileri retrospektif olarak incelendi. Adalimumab haftada 40 mg subkutan olarak uygulandı. Tedavi süresince enfeksiyonlar ve olası diğer yan etkiler açısından hastalar yakın takibe alındı. Hastalarda nodül, apse ve fistüller tedavinin başında, tedavinin 4. haftasında ve 12. haftasında sayı olarak belirlendi. Tedavi öncesi ve tedavinin 12. haftasında kayıt altına alınan global ağrı skorlarının, hastaların yaşam kalite indeks skorlarının ve C-reaktif protein (CRP) düzeylerinin değerleri, tedavi öncesi ve tedavinin 12. haftasında incelendi. Bulgular: Şiddetli HS nedeniyle adalimumab alan 9 hastanın yaşları 33-67 (ortalama 50,6) arasında olup, hastaların 7'si erkekti. Hastalık süreleri 2-25 yıl (ortalama 13 yıl) arasında değişmekte idi. Hastaların 5'i Hurley sınıflamasına göre evre 2, 4'ü ise evre 3 olarak tespit edildi. On ikinci haftada yapılan değerlendirmede nodül sayısında %60,2, apse sayısında %69,3 ve akıntılı fistül sayısında %52,1 azalma saptandı. Tedavinin başlangıcında ortalama 16,3 mg/L olan CRP düzeyleri 12. haftada 5,5 mg/L olarak tespit edildi. Hastalara tedavi öncesi uygulanan yaşam kalite indeksi skoru ortalama 23,4 iken 12 haftanın sonunda skor 6,8'e gerileyerek, hastaların yaşam kalitesinde belirgin düzelme saptandı. Tedav...

show abstract

Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa

Cited by 28 publications

References 26 publications

A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa

A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa

<p>Systematic review of immunomodulatory therapies for hidradenitis suppurativa</p>

The efficacy of adalimumab therapy in refractory hidradenitis suppurativa: Retrospective analysis

Contact Info

Product

Resources

About